Attributable Risk Estimate of Severe Psoriasis on Major Cardiovascular Events

Overview

Journal Am J Med

Specialty General Medicine

Date 2011 Jul 27

PMID 21787906

Citations 114

Authors

Nehal N Mehta

Yiding Yu

Rebecca Pinnelas

Parasuram Krishnamoorthy

Daniel B Shin

Andrea B Troxel

Joel M Gelfand

Affiliations

Soon will be listed here.

Abstract

Background: Recent studies suggest that psoriasis, particularly if severe, may be a risk factor for major adverse cardiac events, such as myocardial infarction, stroke, and mortality from cardiovascular disease. We compared the risk of major adverse cardiac events between patients with psoriasis and the general population and estimated the attributable risk of severe psoriasis.

Methods: We performed a cohort study in the General Practice Research Database. Severe psoriasis was defined as receiving a psoriasis diagnosis and systemic therapy (N=3603). Up to 4 patients without psoriasis were selected from the same practices and start dates for each patient with psoriasis (N=14,330).

Results: Severe psoriasis was a risk factor for major adverse cardiac events (hazard ratio 1.53; 95% confidence interval, 1.26-1.85) after adjusting for age, gender, diabetes, hypertension, tobacco use, and hyperlipidemia. After fully adjusted analysis, severe psoriasis conferred an additional 6.2% absolute risk of 10-year major adverse cardiac events.

Conclusion: Severe psoriasis confers an additional 6.2% absolute risk of a 10-year rate of major adverse cardiac events compared with the general population. This potentially has important therapeutic implications for cardiovascular risk stratification and prevention in patients with severe psoriasis. Future prospective studies are needed to validate these findings.

Citing Articles

Long-Term Safety of Ixekizumab Treatment in Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: a Post Hoc Analysis of Cerebro-Cardiovascular Events.

Lebwohl M, Deodhar A, Schwartzman S, Salvarani C, Feely McDonald M, Bello N Dermatol Ther (Heidelb). 2025; 15(1):161-188.

PMID: 39843709 PMC: 11785857. DOI: 10.1007/s13555-024-01323-9.

Cardiovascular Complications During Delivery Hospitalization in Patients With Psoriasis.

Agrawal A, Sorathia S, Bhagat U, Zahid S, Arockiam A, Bayat A JACC Adv. 2025; 4(2):101562.

PMID: 39837132 PMC: 11787633. DOI: 10.1016/j.jacadv.2024.101562.

Treating adult patients of severe psoriasis with methotrexate leads to reduction in biomarkers of atherosclerosis: A prospective study.

Neema S, Vasudevan B, Misra P, Rai R, Sibin M, Vendhan S Med J Armed Forces India. 2024; 80(Suppl 1):S174-S179.

PMID: 39734852 PMC: 11670649. DOI: 10.1016/j.mjafi.2023.03.004.

Beyond the Heart: The Predictive Role of Coronary Artery Calcium Scoring in Non-Cardiovascular Disease Risk Stratification.

Cortiana V, Vaghela H, Bakhle R, Santhosh T, Kaiwan O, Tausif A Diagnostics (Basel). 2024; 14(21).

PMID: 39518317 PMC: 11545064. DOI: 10.3390/diagnostics14212349.

Using Guidelines of Care to Lower Cardiovascular Risk in Patients with Psoriasis.

Song W, Soffer D, Gelfand J Dermatol Clin. 2024; 42(3):417-428.

PMID: 38796273 PMC: 11128720. DOI: 10.1016/j.det.2024.02.008.

References

Ahlehoff O, Gislason G, Charlot M, Jorgensen C, Lindhardsen J, Olesen J . Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med. 2010; 270(2):147-57. DOI: 10.1111/j.1365-2796.2010.02310.x. View

Jick H, Jick S, Derby L . Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ. 1991; 302(6779):766-8. PMC: 1669537. DOI: 10.1136/bmj.302.6779.766. View

Gibbs R, Newson R, Lawrenson R, Greenhalgh R, Davies A . Diagnosis and initial management of stroke and transient ischemic attack across UK health regions from 1992 to 1996: experience of a national primary care database. Stroke. 2001; 32(5):1085-90. DOI: 10.1161/01.str.32.5.1085. View

von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007; 370(9596):1453-7. DOI: 10.1016/S0140-6736(07)61602-X. View

Prodanovich S, Prodanowich S, Ma F, Taylor J, Pezon C, Fasihi T . Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol. 2005; 52(2):262-7. DOI: 10.1016/j.jaad.2004.06.017. View

Gelfand J, Neimann A, Shin D, Wang X, Margolis D, Troxel A . Risk of myocardial infarction in patients with psoriasis. JAMA. 2006; 296(14):1735-41. DOI: 10.1001/jama.296.14.1735. View

Khan N, Harrison S, Rose P . Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract. 2010; 60(572):e128-36. PMC: 2828861. DOI: 10.3399/bjgp10X483562. View

Abuabara K, Azfar R, Shin D, Neimann A, Troxel A, Gelfand J . Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol. 2010; 163(3):586-92. PMC: 2966545. DOI: 10.1111/j.1365-2133.2010.09941.x. View

Hammad T, McAdams M, Feight A, Iyasu S, Dal Pan G . Determining the predictive value of Read/OXMIS codes to identify incident acute myocardial infarction in the General Practice Research Database. Pharmacoepidemiol Drug Saf. 2008; 17(12):1197-201. DOI: 10.1002/pds.1672. View

10.

. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285(19):2486-97. DOI: 10.1001/jama.285.19.2486. View

11.

Alexandroff A, Pauriah M, Camp R, Lang C, Struthers A, Armstrong D . More than skin deep: atherosclerosis as a systemic manifestation of psoriasis. Br J Dermatol. 2009; 161(1):1-7. DOI: 10.1111/j.1365-2133.2009.09281.x. View

12.

Brauchli Y, Jick S, Miret M, Meier C . Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case-control analysis. Br J Dermatol. 2009; 160(5):1048-56. DOI: 10.1111/j.1365-2133.2008.09020.x. View

13.

Wilson P, DAgostino R, Levy D, Belanger A, Silbershatz H, Kannel W . Prediction of coronary heart disease using risk factor categories. Circulation. 1998; 97(18):1837-47. DOI: 10.1161/01.cir.97.18.1837. View

14.

Nightingale A, Farmer R . Ischemic stroke in young women: a nested case-control study using the UK General Practice Research Database. Stroke. 2004; 35(7):1574-8. DOI: 10.1161/01.STR.0000129789.58837.e4. View

15.

Krueger G, Koo J, Lebwohl M, Menter A, Stern R, Rolstad T . The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001; 137(3):280-4. View

16.

DAgostino Sr R, Vasan R, Pencina M, Wolf P, Cobain M, Massaro J . General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008; 117(6):743-53. DOI: 10.1161/CIRCULATIONAHA.107.699579. View

17.

Prodanovich S, Kirsner R, Kravetz J, Ma F, Martinez L, Federman D . Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol. 2009; 145(6):700-3. DOI: 10.1001/archdermatol.2009.94. View

18.

Mehta N, Azfar R, Shin D, Neimann A, Troxel A, Gelfand J . Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2009; 31(8):1000-6. PMC: 2894736. DOI: 10.1093/eurheartj/ehp567. View

19.

Neimann A, Shin D, Wang X, Margolis D, Troxel A, Gelfand J . Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006; 55(5):829-35. DOI: 10.1016/j.jaad.2006.08.040. View

20.

Davidovici B, Sattar N, Prinz J, Jorg P, Puig L, Emery P . Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010; 130(7):1785-96. DOI: 10.1038/jid.2010.103. View